US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Maison Solutions

0.9785

+0.00730.75%

Post-market: 0.97850.00000.00%16:44 EDT

Volume:55.23K

Turnover:53.97K

Market Cap:19.27M

PE:-13.33

High:0.9899

Open:0.9755

Low:0.9710

Close:0.9712

Loading ...

Overview Company News Filings

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

BRIEF-Maison Solutions Files Prospectus For Proposed Resale From Time To Time By Selling Stockholder Of Up To 62.7 Million Shares Of Class A Common Stock

Maison Solutions Inc. (NASDAQ:MSS) Might Not Be As Mispriced As It Looks After Plunging 25%

Simply Wall St.

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Maison Solutions Names Xintong Ma as Chief Strategy Officer

MT Newswires Live

Maison Solutions Q3 Gross Profit USD 7.5 Million

Maison Solutions Q3 Sales $34.1M Up From $13.6M YoY

Maison Solutions Reports Third Quarter and Nine-Month 2025 Financial Results

ACCESS Newswire

PUB warns of flash floods as wetter weather expected Mar 19 to 21 due to monsoon surge

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Is MagnaChip Semiconductor Corporation (MX) the Best Semiconductor Penny Stock To Invest In Right Now?

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Maison Solutions Inc. Appoints New COO Jacob Cao

Maison Solutions appoints Jacob Cao as COO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSS\",,,,,undefined,":{"symbol":"MSS","market":"US","secType":"STK","nameCN":"Maison Solutions","latestPrice":0.9785,"timestamp":1745611200000,"preClose":0.9712,"halted":0,"volume":55225,"hourTrading":{"tag":"盘后","latestPrice":0.9785,"preClose":0.9785,"latestTime":"16:44 EDT","volume":3,"amount":2.82,"timestamp":1745613864037},"delay":0,"floatShares":6157619,"shares":19690476,"eps":-0.073391,"marketStatus":"Market Closed","change":0.0073,"latestTime":"04-25 16:00:00 EDT","open":0.9755,"high":0.9899,"low":0.971,"amount":53970.77398,"amplitude":0.01946,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.073391,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1686801600000,"exchange":"NASDAQ","adjPreClose":0.9712,"preHourTrading":{"tag":"盘前","latestPrice":0.9812,"preClose":0.9849,"latestTime":"07:27 EDT","volume":2,"amount":1.9624,"timestamp":1745580424629},"postHourTrading":{"tag":"盘后","latestPrice":0.9785,"preClose":0.9785,"latestTime":"16:44 EDT","volume":3,"amount":2.82,"timestamp":1745613864037},"volumeRatio":1.03054788539307},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSS\",,,,,undefined,":{"symbol":"MSS","floatShares":6157619,"roa":"0.97%","roe":"-12.63%","lyrEps":-0.186459,"volumeRatio":1.03054788539307,"shares":19690476,"dividePrice":0,"high":0.9899,"amplitude":0.01946,"preClose":0.9712,"low":0.971,"week52Low":0.6005,"pbRate":"1.61","psRate":"0.17","week52High":2.08,"institutionHeld":0,"latestPrice":0.9785,"eps":-0.073391,"divideRate":0,"volume":55225,"delay":0,"ttmEps":-0.073391,"open":0.9755,"prevYearClose":1.22,"prevWeekClose":1.0099,"prevMonthClose":1.03,"prevQuarterClose":1.03,"fiveDayClose":1.0099,"twentyDayClose":1.13,"sixtyDayClose":1.1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529803206","title":"Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529803206","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529803206?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:05","pubTimestamp":1745417100,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, April 23, 2025  -- Adagene Inc.  , a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3.Abstract Title:Safety and Efficacy of ADG126  in Combination with Pembrolizumab: Updated Results of Phase 1b/2 Study in Advanced MSS CRC. Poster will be made available on the Publications page of the company’s websitehere.Powered by its proprietaryDynamic Precision Library platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while min","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adagene-announces-upcoming-poster-presentation-140500747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSS","BK4113","CRC","BK4117","ADAG","BK4107","BK4139","BK4213","LU0456854461.SGD","AFG","LU0266512127.USD"],"gpt_icon":0},{"id":"2527492277","title":"Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492277","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492277?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET. CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ --Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will host a virtual key opinion leader  event featuring Zev A. Wainberg, MD, Professor of Medicine at University of California, Los Angeles  and co-director of the UCLA GI Oncology Program, on Wednesday, April 23, 2025 at 2:30 p.m. ET. To register, please click here.Dr. Wainberg will connect with Leap's Chief Medical Officer, Cynthia Sirard, MD, to discuss the unmet need and how sirexatamab  may improve upon the current treatment landscape for previously treated patients with advanced microsatellite stable  colorectal cancer .The event will focus on reviewing the positive data from Part B of the Phase 2 DeFianCe study of sirexatamab in second-line patients with advanced MSS CRC. Sirexatamab, Leap's most advanced clinical program, is a humanize","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-host-virtual-kol-110000836.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-host-virtual-kol-110000836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HST","MSS","BK4213","IE00B66KJ199.SGD","CRC","BK4505","BK4139","BK4218","BK4585","IE00B19Z4B17.USD","BK4588","AEIS","KOL","LENZ","IE00B7SZL793.SGD","LPTX","BK4563","LU0266512127.USD","BK4007","BK4181","BK4113","IE0031619046.USD","LU0456854461.SGD","BK4157"],"gpt_icon":0},{"id":"2526647980","title":"BRIEF-Maison Solutions Files Prospectus For Proposed Resale From Time To Time By Selling Stockholder Of Up To 62.7 Million Shares Of Class A Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2526647980","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526647980?lang=en_us&edition=fundamental","pubTime":"2025-04-12 05:55","pubTimestamp":1744408506,"startTime":"0","endTime":"0","summary":"BRIEF-Maison Solutions Files Prospectus For Proposed Resale From Time To Time By Selling Stockholder Of Up To 62.7 Million Shares Of Class A Common StockApril 11  - Maison Solutions Inc MSS.O:MAISON SOLUTIONS FILES PROSPECTUS FOR PROPOSED RESALE FROM TIME TO TIME BY SELLING STOCKHOLDER OF UP TO 62.7 MILLION SHARES OF CLASS A COMMON STOCKSource text: [ID:n0001213900-25-031176]Further company coverage: MSS.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP1SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4113","MSS"],"gpt_icon":0},{"id":"2526671986","title":"Maison Solutions Inc. (NASDAQ:MSS) Might Not Be As Mispriced As It Looks After Plunging 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526671986","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526671986?lang=en_us&edition=fundamental","pubTime":"2025-04-11 18:52","pubTimestamp":1744368743,"startTime":"0","endTime":"0","summary":"Maison Solutions Inc. ( NASDAQ:MSS ) shares have had a horrible month, losing 25% after a relatively good period...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/5023000-choice2-main-header/1585186769297","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5023000-choice2-main-header/1585186769297"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/consumer-retailing/nasdaq-mss/maison-solutions/news/maison-solutions-inc-nasdaqmss-might-not-be-as-mispriced-as-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BGHQF748.EUR",".IXIC","QLD","SQQQ","IE00BKPKM429.USD","NQmain","PSQ","LU2210150020.SGD","TQQQ","IE00B3QW5Z07.USD","LU2095319765.USD","MNQmain","LU2210149790.SGD","TSYW.SI","BK4588","NDAQ","MSS","BK4113","BK4585","QID","IE00B64PRP62.GBP","BK4112","USAW.SI","NVIW.SI","USJW.SI"],"gpt_icon":1},{"id":"2525017693","title":"Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2525017693","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525017693?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, April  07, 2025  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056677/0/en/Adagene-to-Present-at-Stifel-s-2025-Virtual-Targeted-Oncology-Forum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSS","ADAG","BK4179","LU0266512127.USD","SF","CRC","BK4213","FET","BK4127","BK4139","BK4113","LU0456854461.SGD"],"gpt_icon":0},{"id":"2522558078","title":"Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522558078","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522558078?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"– Initial clinical activity in a PD-1 resistant population, with an ORR almost three times higher than historical PD-1 rechallenge response rates, with data still maturing –。– One durable complete response in a Merkel Cell Carcinoma  patient and two partial responses , including one in a second MCC patient and one in a microsatellite instability-high  Colorectal Cancer  patient, all of whom were previously treated with and progressed on immunotherapy –。– All PD-1 resistant “hot” tumor patients with tumor shrinkage remain on study, suggesting potential for deepening responses over time –。The Phase 1 dose expansion trial is a multi-center, open-label, dose expansion study evaluating solnerstotug as monotherapy and in combination withLibtayo , Regeneron’s PD-1 inhibitor, in both a basket of “hot” tumorsthat typically respond to immunotherapy but have progressed on prior PD-1 therapy and a single “cold” tumor histology  that is typically unresponsive to immunotherapy.At the time of this da","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sensei-biotherapeutics-reports-favorable-preliminary-200500147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053666078.USD","LU2065731478.USD","BK4139","LU1169590202.USD","BK4113","LU1169589451.USD","CRC","IE0031619046.USD","IE00B66KJ199.SGD","PR","RCC","BK4107","SITC","BK4161","BK4023","BK4080","CRS","SD","LU0456854461.SGD","MSS","PD","LU0266512127.USD","CR","IE00B7SZL793.SGD","L","BK4006","IE00B19Z4B17.USD","BK4213","BK4585","BK4231","BK4588","SNSE"],"gpt_icon":0},{"id":"2522455332","title":"Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522455332","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522455332?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:29","pubTimestamp":1743010151,"startTime":"0","endTime":"0","summary":"Leap Therapeutics, Inc. presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab  in combination with bevacizumab and chemotherapy  compared to bevacizumab and chemotherapy .The trial enrolled patients with advanced microsatellite stable  colorectal cancer  who have received one prior systemic therapy for advanced disease.The updated analysis shared on Wednesday includes the overall response rate , an additional two months of patient follow-up for progression-free survival , and initial overall survival  data.As ofMarch 12, 2025, 34 patients remain on the study drug in the sirexatamab Experimental Arm compared to 24 patients in the Control Arm.In patients with highDKK1levels, the sirexatamab Experimental Arm has a statistically significant 32% higher ORR, 3.5 months longer PFS, and OS compared to the Control Arm:. In patients who had not received prior anti-VEGF therapy, the sirexatamab Experimental Arm has a statistically significant 22%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/penny-stock-leap-therapeutics-unveils-172911695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4141","BK4543","IE00BMPRXR70.SGD","LENZ","CRC","BK4195","BK4213","BK4211","LU0456854461.SGD","LU0266512127.USD","ORR","BK4505","BK4588","BK4097","IE00BMPRXN33.USD","BK4563","BK4609","LU0348723411.USD","MSS","BK4113","OS","BK4585","IE00BMPRXQ63.HKD","PFS","LPTX","ONC"],"gpt_icon":1},{"id":"2522187556","title":"Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187556","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187556?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:05","pubTimestamp":1742987100,"startTime":"0","endTime":"0","summary":"Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET. CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab  in second-line patients with advanced microsatellite stable  colorectal cancer  confirming:. Statistically significant 22% higherORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy. FL-501 abstract accepted for poster presentation at the 2025 American Association for Cancer Research  Annual Meeting.Across the intent-to-treat population, thesirexatamab Experimental Arm had improved ORR compared to the Control Arm, with PFS and OS maturing with a higher number of patients continuing to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4113","LPTX","LU0348723411.USD","BK4097","IE00BMPRXN33.USD","CRC","ORR","BK4213","BK4141","BK4585","PFS","BK4609","BK4195","IE00BMPRXQ63.HKD","LENZ","IE00BMPRXR70.SGD","BK4563","BK4505","BK4588","LU0266512127.USD","LU0456854461.SGD","BK4139","BK4211","OS","MSS","BK4543"],"gpt_icon":1},{"id":"2522596875","title":"Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522596875","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522596875?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFSin second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy. Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prioranti-VEGF therapy. Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET. \"The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can generate significantly higher ORR and longer PFS in CRC patients who have high levels of DKK1 or who have not had prior anti-VEGF therapy, two exploratory populations with strong scientific rationale. In the full intent-to-treat population, sirexatamab demonstrated a higher ORR and a tail population with longer PFS that continues to mature. With more sirexatamab-treated patients currently continuing on study drug than control arm patients, there is potential for the dataset to continue t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXQ63.HKD","LU0456854461.SGD","BK4211","CRC","LU0266512127.USD","LPTX","BK4505","BK4563","BK4585","BK4213","BK4097","IE00BMPRXR70.SGD","BK4113","BK4141","BK4609","ORR","BK4195","LU0348723411.USD","PFS","BK4588","MSS","BK4543","BK4139","LENZ","IE00BMPRXN33.USD","ARM","OS"],"gpt_icon":0},{"id":"2521747504","title":"Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747504?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses. SAFEbody technology utilized to create masked T cell engagers for potentially superior safety profile with enhanced therapeutic index. Cash balance of $85.2 million provides runway into late 2026. SAN DIEGO and SUZHOU, China, March 24, 2025  -- Adagene Inc.  , a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel anti-body-based therapies, today reported financial results for the full year 2024 and provided corporate updates.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adagene-reports-full-2024-financial-120000486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456854461.SGD","BK4113","LU0266512127.USD","CRC","MSS","BK4213","HCC","ADAG","BK4006","BK4139"],"gpt_icon":0},{"id":"2521478984","title":"Maison Solutions Names Xintong Ma as Chief Strategy Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521478984","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521478984?lang=en_us&edition=fundamental","pubTime":"2025-03-21 16:06","pubTimestamp":1742544373,"startTime":"0","endTime":"0","summary":"Maison Solutions (MSS) said late Thursday it appointed Xintong Ma as new chief strategy officer in a consulting role.Ma founded Zhekou Niu Information Technology in 2019.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4595","BK4588","MSS","BK4113","BK4516","BK4585","BK4023","STRK","BK4596","BK4600"],"gpt_icon":0},{"id":"2520684939","title":"Maison Solutions Q3 Gross Profit USD 7.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520684939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520684939?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:52","pubTimestamp":1742248370,"startTime":"0","endTime":"0","summary":"Mar 17 (Reuters) - Maison Solutions Q3 gross margin 22.1%.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 17-MAR-202521:41:23.073 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nRSDcCnfL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4113","MSS"],"gpt_icon":0},{"id":"2520768437","title":"Maison Solutions Q3 Sales $34.1M Up From $13.6M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2520768437","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520768437?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:44","pubTimestamp":1742247840,"startTime":"0","endTime":"0","summary":"Maison Solutions Q3 Sales $34.1M Up From $13.6M YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44366867/maison-solutions-q3-sales-34-1m-up-from-13-6m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maison Solutions Q3 Sales $34.1M Up From $13.6M YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSS"],"gpt_icon":0},{"id":"2520847606","title":"Maison Solutions Reports Third Quarter and Nine-Month 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520847606","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520847606?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:40","pubTimestamp":1742247600,"startTime":"0","endTime":"0","summary":"MONTEREY PARK, CA / ACCESS Newswire / March 17, 2025 / Maison Solutions Inc.  , a U.S.-based specialty grocery retailer offering traditional Asian and international food and merchandise, today announced financial results for the third quarter and nine-months ended January 31, 2025.Total net revenues for the third quarter increased 151.1% to $34.1 million compared to $13.6 million in the same period last fiscal year. The increase was primarily driven by the inclusion of revenues from the newly acquired subsidiary, Lee Lee International Supermarkets   and increased sales of Maison El Monte.Total cost of revenues for the third quarter was $26.6 million compared to $10.4 million in the same period last fiscal year. The increase was primarily due to the inclusion of the newly acquired subsidiary, Lee Lee.Gross profit for the third quarter was $7.5 million, while gross margin was 22.1%. Gross profit for the same period last fiscal year was $3.2 million, while gross","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maison-solutions-reports-third-quarter-214000108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSS","BK4113"],"gpt_icon":0},{"id":"2520524649","title":"PUB warns of flash floods as wetter weather expected Mar 19 to 21 due to monsoon surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2520524649","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520524649?lang=en_us&edition=fundamental","pubTime":"2025-03-17 18:31","pubTimestamp":1742207460,"startTime":"0","endTime":"0","summary":"The surge will also bring lower daily minimum temperatures of around 22 degrees Celsius.","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--F9SXzsQI--/c_crop,h_843,w_1500,x_0,y_70/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2023/03/03/img_0665.jpg?itok=QmXMm6c3","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--F9SXzsQI--/c_crop,h_843,w_1500,x_0,y_70/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2023/03/03/img_0665.jpg?itok=QmXMm6c3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/flash-flood-warning-pub-march-2025-weather-monsoon-surge-rain-met-service-5005251","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["MSS","BK4113"],"gpt_icon":0},{"id":"2519835947","title":"Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2519835947","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519835947?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:00","pubTimestamp":1741867200,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, March  13, 2025  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042117/0/en/Adagene-to-Present-at-11th-Annual-Immuno-Oncology-360-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG","MSS","BK4211","LU0266512127.USD","BK4113","SMMF","CRC","LU0456854461.SGD","BK4213"],"gpt_icon":0},{"id":"2517112202","title":"Is MagnaChip Semiconductor Corporation (MX) the Best Semiconductor Penny Stock To Invest In Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517112202","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517112202?lang=en_us&edition=fundamental","pubTime":"2025-03-07 07:26","pubTimestamp":1741303605,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Semiconductor Penny Stocks To Invest In Right Now.In this article, we are going to take a look at where MagnaChip Semiconductor Corporation  stands against the other semiconductor penny stocks.One of the biggest news items from last month was that Trump wanted to kill the CHIPS Act. Why was it a huge scandal that the president threatened to “alter federal government contracts with chipmakers and slap new tariffs on the semiconductor industry”?The answer lies in analyzing the semiconductor space and appreciating just how much of an essential industry chipmaking has become.Semiconductors, or chips, are the backbone of modern electronic devices. The materials and the accompanying technologies have become central to many industries, especially artificial intelligence . They are especially critical in the current age of AI because they provide the necessary processing power for AI computations. As such, advances in semiconductor technology are the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/magnachip-semiconductor-corporation-mx-best-232645603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MX","BK4518","MSS","BK4141","BK4113","BK4539","IACC"],"gpt_icon":0},{"id":"2516760687","title":"Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2516760687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516760687?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:01","pubTimestamp":1741003260,"startTime":"0","endTime":"0","summary":"– $7.7 million in Revuforj  net product revenue in initial five weeks of launch –。– Launched Niktimvo  in the U.S. in late January, in partnership with Incyte –。–sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial –。–$692.4 million in cash, cash equivalents and investments expected to fund the company to profitability –。NEW YORK, March 03, 2025  -- Syndax Pharmaceuticals , a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter and full year endedDecember 31, 2024, and provided a business update.Reported additional positive results from a post-hoc efficacy analysis of all 77 R/R mNPM1 AML patients who met the efficacy evaluabl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-reports-fourth-quarter-full-120100660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","BK4533","BK4107","BK4139","MSS","ASH","BK4588","LU0456854461.SGD","LU0266512127.USD","BK4585","BK4161","LU2463526074.USD","SNDX","HSTC","LU2355687059.USD","BK4109","CR","BK4113","LU0985320562.USD","CRC","LU1571399168.USD","LU1699723380.USD","ORR","ALL"],"gpt_icon":0},{"id":"2514351792","title":"Maison Solutions Inc. Appoints New COO Jacob Cao","url":"https://stock-news.laohu8.com/highlight/detail?id=2514351792","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514351792?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:51","pubTimestamp":1740696664,"startTime":"0","endTime":"0","summary":"Maison Solutions Inc. Class A ( ($MSS) ) has shared an update. On February 21, 2025, Tao Han resigned as Chief Operating Officer of Maison Solution...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maison-solutions-inc-appoints-new-coo-jacob-cao?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maison-solutions-inc-appoints-new-coo-jacob-cao?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1992135472.HKD","LU2211815571.USD","BK4113","MSS","GB00BDT5M118.USD","COO","LU2272731600.USD","BK4585","BK4198","BK4588","LU2272731782.SGD","LU1992135399.USD"],"gpt_icon":0},{"id":"2514435909","title":"Maison Solutions appoints Jacob Cao as COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2514435909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514435909?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:40","pubTimestamp":1740696028,"startTime":"0","endTime":"0","summary":"Maison Solutions (MSS) announced the appointment of Jacob Cao as its new COO. In this role, Cao will oversee operating strategies with a focus on i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maison-solutions-appoints-jacob-cao-as-coo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maison-solutions-appoints-jacob-cao-as-coo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4113","LU2272731600.USD","GB00BDT5M118.USD","COO","BK4588","BK4198","LU2272731782.SGD","LU1992135399.USD","LU1992135472.HKD","BK4585","LU2211815571.USD","MSS"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MSS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MSS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MSS","date":"2025-04-25","current":-14.475179,"percent":0.298103,"low":-131.978833,"twenty":-90.258195,"median":-7.745137,"eighty":22.943984,"high":171.736597,"avg":-10.648471,"sd":64.606106,"marketCap":19123390},"quantilePoints":[{"date":"2023-10-06","current":95.051104,"twenty":42.433528,"median":42.433528,"eighty":52.957043,"marketCap":165760000},{"date":"2023-10-13","current":53.890581,"twenty":42.433528,"median":52.19324,"eighty":70.694259,"marketCap":93980000},{"date":"2023-10-20","current":85.821811,"twenty":42.433528,"median":55.481838,"eighty":70.694259,"marketCap":149665000},{"date":"2023-10-27","current":82.74538,"twenty":44.046002,"median":56.330509,"eighty":81.726975,"marketCap":144300000},{"date":"2023-11-03","current":84.12447,"twenty":51.089968,"median":63.915503,"eighty":85.482343,"marketCap":146705000},{"date":"2023-11-10","current":96.960613,"twenty":53.551113,"median":69.378819,"eighty":87.328201,"marketCap":169090000},{"date":"2023-11-17","current":98.817079,"twenty":54.208832,"median":80.199368,"eighty":94.520685,"marketCap":172327500},{"date":"2023-11-24","current":140.573349,"twenty":55.481838,"median":84.97314,"eighty":96.960613,"marketCap":245146426},{"date":"2023-12-01","current":163.945785,"twenty":56.330509,"median":86.140063,"eighty":104.492564,"marketCap":285905711},{"date":"2023-12-08","current":163.719965,"twenty":58.240018,"median":88.420865,"eighty":140.573349,"marketCap":285511902},{"date":"2023-12-15","current":171.736597,"twenty":59.40694,"median":91.656421,"eighty":155.816242,"marketCap":299492139},{"date":"2023-12-22","current":25.627315,"twenty":53.890581,"median":88.420865,"eighty":152.316023,"marketCap":33473809},{"date":"2023-12-29","current":20.803349,"twenty":47.270951,"median":87.625236,"eighty":147.980266,"marketCap":27172856},{"date":"2024-01-05","current":17.336124,"twenty":42.433528,"median":86.087021,"eighty":144.841359,"marketCap":22644047},{"date":"2024-01-12","current":13.568909,"twenty":34.099403,"median":84.12447,"eighty":143.192868,"marketCap":17723397},{"date":"2024-01-19","current":11.411692,"twenty":24.572072,"median":77.653357,"eighty":140.573349,"marketCap":14905690},{"date":"2024-01-26","current":12.831747,"twenty":17.788371,"median":69.166652,"eighty":140.573349,"marketCap":16760533},{"date":"2024-02-02","current":13.733225,"twenty":15.074891,"median":59.40694,"eighty":106.508156,"marketCap":17938023},{"date":"2024-02-09","current":16.58238,"twenty":14.125173,"median":55.906174,"eighty":105.447318,"marketCap":21659523},{"date":"2024-02-16","current":25.175067,"twenty":14.548777,"median":53.466246,"eighty":104.492564,"marketCap":32883094},{"date":"2024-02-23","current":21.104847,"twenty":14.726058,"median":42.433528,"eighty":104.32283,"marketCap":27566666},{"date":"2024-03-01","current":23.064583,"twenty":15.013988,"median":42.433528,"eighty":102.667922,"marketCap":30126428},{"date":"2024-03-08","current":23.818328,"twenty":15.316089,"median":36.028989,"eighty":99.506624,"marketCap":31110952},{"date":"2024-03-15","current":19.29586,"twenty":16.341182,"median":28.039296,"eighty":97.331906,"marketCap":25203809},{"date":"2024-03-22","current":-113.246356,"twenty":14.726058,"median":26.833306,"eighty":95.433006,"marketCap":26188333},{"date":"2024-03-28","current":-118.355211,"twenty":13.992212,"median":25.627315,"eighty":93.459846,"marketCap":27369761},{"date":"2024-04-05","current":-107.286018,"twenty":13.539061,"median":24.948944,"eighty":91.953456,"marketCap":24809999},{"date":"2024-04-12","current":-102.177162,"twenty":13.066915,"median":24.270574,"eighty":90.128814,"marketCap":23628571},{"date":"2024-04-19","current":-103.880113,"twenty":11.529276,"median":23.969076,"eighty":89.04676,"marketCap":24022380},{"date":"2024-04-26","current":-93.662397,"twenty":-30.862157,"median":23.667579,"eighty":88.304173,"marketCap":21659523},{"date":"2024-05-03","current":-88.553541,"twenty":-92.12974,"median":23.064583,"eighty":87.710103,"marketCap":20478095},{"date":"2024-05-10","current":-102.177162,"twenty":-99.62273,"median":22.913834,"eighty":86.734132,"marketCap":23628571},{"date":"2024-05-17","current":-103.028636,"twenty":-100.474208,"median":21.858591,"eighty":86.076413,"marketCap":23825475},{"date":"2024-05-24","current":-91.959447,"twenty":-100.474208,"median":20.803349,"eighty":85.906678,"marketCap":21265714},{"date":"2024-05-31","current":-92.81092,"twenty":-100.474208,"median":19.29586,"eighty":85.142875,"marketCap":21462618},{"date":"2024-06-07","current":-97.068302,"twenty":-100.474208,"median":18.391367,"eighty":83.572834,"marketCap":22447142},{"date":"2024-06-14","current":-120.909639,"twenty":-100.474208,"median":17.562248,"eighty":81.726975,"marketCap":27960475},{"date":"2024-06-21","current":-108.137496,"twenty":-102.177162,"median":16.808503,"eighty":77.653357,"marketCap":25006904},{"date":"2024-06-28","current":-123.464072,"twenty":-102.177162,"median":15.979384,"eighty":77.483623,"marketCap":28551190},{"date":"2024-07-05","current":-112.394878,"twenty":-102.177162,"median":14.922634,"eighty":75.658981,"marketCap":25991428},{"date":"2024-07-12","current":-108.988973,"twenty":-103.709818,"median":14.125173,"eighty":69.293952,"marketCap":25203809},{"date":"2024-07-15","current":-110.691923,"twenty":-104.385891,"median":14.100299,"eighty":69.209085,"marketCap":25597618},{"date":"2024-08-02","current":-90.256492,"twenty":-104.217298,"median":14.075425,"eighty":69.124218,"marketCap":20871904},{"date":"2024-08-09","current":-77.484348,"twenty":-103.369227,"median":13.651067,"eighty":68.636233,"marketCap":17918333},{"date":"2024-08-16","current":-5.24654,"twenty":-103.028636,"median":13.49655,"eighty":63.01379,"marketCap":17524523},{"date":"2024-08-23","current":-3.995564,"twenty":-102.773194,"median":13.146812,"eighty":58.706787,"marketCap":13346007},{"date":"2024-08-30","current":-4.22317,"twenty":-102.347457,"median":12.831747,"eighty":57.094313,"marketCap":14106257},{"date":"2024-09-06","current":-4.83448,"twenty":-102.177162,"median":11.607666,"eighty":55.991041,"marketCap":16148159},{"date":"2024-09-13","current":-4.347554,"twenty":-102.177162,"median":11.115471,"eighty":54.845335,"marketCap":14521726},{"date":"2024-09-20","current":-4.715991,"twenty":-102.177162,"median":-3.808162,"eighty":53.720847,"marketCap":15752380},{"date":"2024-09-27","current":-10.100234,"twenty":-102.177162,"median":-3.90838,"eighty":52.278107,"marketCap":25597618},{"date":"2024-10-04","current":-9.478681,"twenty":-102.177162,"median":-3.985012,"eighty":47.270951,"marketCap":24022380},{"date":"2024-10-11","current":-9.711763,"twenty":-101.836571,"median":-4.110575,"eighty":42.433528,"marketCap":24613095},{"date":"2024-10-18","current":-8.235575,"twenty":-101.325685,"median":-4.244392,"eighty":42.433528,"marketCap":20871904},{"date":"2024-10-25","current":-7.847105,"twenty":-100.985094,"median":-4.358165,"eighty":42.433528,"marketCap":19887380},{"date":"2024-10-31","current":-7.110564,"twenty":-100.474208,"median":-4.421241,"eighty":41.484268,"marketCap":18020723},{"date":"2024-11-08","current":-8.157881,"twenty":-100.474208,"median":-4.598091,"eighty":37.35558,"marketCap":20674999},{"date":"2024-11-15","current":-7.614022,"twenty":-100.474208,"median":-4.763445,"eighty":35.546593,"marketCap":19296666},{"date":"2024-11-22","current":-7.610915,"twenty":-100.474208,"median":-4.848628,"eighty":32.682364,"marketCap":19288790},{"date":"2024-11-29","current":-7.304023,"twenty":-100.474208,"median":-5.421621,"eighty":28.94379,"marketCap":18511016},{"date":"2024-12-06","current":-6.992469,"twenty":-99.62273,"median":-5.705759,"eighty":27.134803,"marketCap":17721428},{"date":"2024-12-13","current":-8.080187,"twenty":-99.62273,"median":-6.992469,"eighty":27.134803,"marketCap":20478095},{"date":"2024-12-20","current":-7.310906,"twenty":-99.62273,"median":-7.07094,"eighty":26.833306,"marketCap":21068809},{"date":"2024-12-27","current":-7.925842,"twenty":-98.26037,"median":-7.186705,"eighty":25.868513,"marketCap":22840952},{"date":"2025-01-03","current":-8.472451,"twenty":-97.408893,"median":-7.304023,"eighty":25.627315,"marketCap":24416190},{"date":"2025-01-10","current":-8.814083,"twenty":-97.068302,"median":-7.345923,"eighty":25.446416,"marketCap":25400714},{"date":"2025-01-17","current":-7.242579,"twenty":-97.068302,"median":-7.379232,"eighty":25.114768,"marketCap":20871904},{"date":"2025-01-24","current":-7.720863,"twenty":-96.727712,"median":-7.38094,"eighty":24.994169,"marketCap":22250237},{"date":"2025-01-31","current":-7.648437,"twenty":-95.195057,"median":-7.420176,"eighty":24.81327,"marketCap":22041518},{"date":"2025-02-07","current":-7.857515,"twenty":-94.513875,"median":-7.443095,"eighty":24.511772,"marketCap":22644047},{"date":"2025-02-14","current":-8.609104,"twenty":-94.343579,"median":-7.452707,"eighty":24.240424,"marketCap":24809999},{"date":"2025-02-21","current":-8.745756,"twenty":-93.662397,"median":-7.458634,"eighty":24.119825,"marketCap":25203809},{"date":"2025-02-28","current":-8.13082,"twenty":-93.662397,"median":-7.515884,"eighty":24.119825,"marketCap":23431666},{"date":"2025-03-07","current":-9.292366,"twenty":-92.81092,"median":-7.526106,"eighty":23.818328,"marketCap":26779047},{"date":"2025-03-14","current":-9.22404,"twenty":-92.81092,"median":-7.54099,"eighty":23.818328,"marketCap":26582142},{"date":"2025-03-21","current":-15.798691,"twenty":-91.959447,"median":-7.58421,"eighty":23.667579,"marketCap":20871904},{"date":"2025-03-28","current":-16.842001,"twenty":-91.959447,"median":-7.614022,"eighty":23.51683,"marketCap":22250237},{"date":"2025-04-04","current":-15.351559,"twenty":-91.107969,"median":-7.646769,"eighty":23.064583,"marketCap":20281190},{"date":"2025-04-11","current":-15.351559,"twenty":-91.107969,"median":-7.652869,"eighty":23.064583,"marketCap":20281190},{"date":"2025-04-17","current":-15.05347,"twenty":-90.433599,"median":-7.691717,"eighty":23.064583,"marketCap":19887380},{"date":"2025-04-25","current":-14.475179,"twenty":-90.258195,"median":-7.745137,"eighty":22.943984,"marketCap":19123390}],"updateTime":1745765011321}}}